Safety and Pharmacokinetics of Atezolizumab Combination Treatments in Participants With HER2-Positive and HER2-Negative Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: HER2-Positive Metastatic Breast Cancer|HER2-Negative Metastatic Breast Cancer|Locally Advanced or Early Breast Cancer
Interventions: DRUG: Atezolizumab|DRUG: Carboplatin|DRUG: Docetaxel|DRUG: Pertuzumab|DRUG: Trastuzumab|DRUG: Trastuzumab emtansine|DRUG: Doxorubicin|DRUG: Cyclophosphamide
Sponsor: Hoffmann-La Roche